Popular acid reflux medication linked to anemia and bone loss
Science Daily
February 26, 2026
AI-Generated Deep Dive Summary
A new study highlights potential risks associated with long-term use of proton pump inhibitors (PPIs), a widely used class of medications for acid reflux, ulcers, and gastritis. Researchers in Brazil found that prolonged use of PPIs like omeprazole (Prilosec), pantoprazole (Protonix), and esomeprazole (Nexium) may disrupt the body's absorption of essential nutrients, leading to anemia and bone loss. The study, published in ACS Omega, revealed that rats treated with omeprazole experienced imbalances in iron, calcium, and other minerals, which could increase the risk of osteoporosis and anemia.
The researchers observed that PPIs, which reduce stomach acid by blocking the proton pump enzyme, may interfere with nutrient absorption. Stomach acid plays a critical role in breaking down food and facilitating the uptake of minerals like iron and calcium. When acid production is suppressed for extended periods, it can lead to deficiencies in these nutrients, as seen in the study's animal models. Blood tests from the treated rats showed higher calcium levels and lower iron levels, which are concerning indicators for bone health and anemia risk.
The study was conducted over 10, 30, and 60 days to reflect varying durations of PPI use in humans. Longer-term effects were more pronounced, with significant changes in mineral distribution across multiple organs, including the liver and spleen. These findings suggest that chronic use of PPIs may have broader systemic impacts on health, particularly when used without medical supervision.
Experts warn about the growing trend of self-medication with PPIs, especially following new regulations allowing over-the-counter
Verticals
scienceresearch
Originally published on Science Daily on 2/26/2026